JPM Parting Shots: Immuno-Oncology Plans For Regeneron, Incyte, Molecular Partners
This article was originally published in Scrip
Discussions with companies during last month's 34th Annual J.P. Morgan Healthcare Conference in San Francisco revealed that immuno-oncology remains as hot as ever with developers of targeted therapeutics shifting their focus to immunotherapies or agents that can be combined with the immune system-harnessing treatments for cancer.
You may also be interested in...
Allergan is building a diverse ophthalmology portfolio with a pipeline of drugs, devices and procedures that could bolster the company’s eye care revenue beyond Restasis and glaucoma medicines.
Regeneron Pharmaceuticals Inc. executives emphasized the blockbuster potential of product candidates in the company's late-stage research and development pipeline on Aug. 4, while noting that the top-selling biologic Eylea (aflibercept) is facing increased reimbursement and competitive pressures.
Doesn't every biopharma company have an immuno-oncology strategy these days? It certainly seems that way, considering the number of drug developers that are labeling their therapeutic candidates as immunotherapies regardless of whether the description truly fits their asset.